Nephrogenic systemic fibrosis is associated with transforming growth factor β and Smad without evidence of renin-angiotensin system involvement

Journal of the American Academy of Dermatology

Volumn 58, Issue 6, 2008, Pages 1025-1030

  Kelly, Brent ^a   Petitt, Matthew ^a   Sanchez, Ramon ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; GADOLINIUM; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEPHROGENIC FIBROSING DERMOPATHY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SKIN BIOPSY;

ADOLESCENT; ADULT; AGED, 80 AND OVER; FEMALE; FIBROSIS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 43249125755     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.02.038     Document Type: Article

References (29)

1. Cowper S.E., Robin H.S., Steinberg S.M., Su L.D., Gupta S., and LeBoit P.E. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356 (2000) 1000-1001
2. Cowper SE. Nephrogenic fibrosing dermopathy [NFD/NSF Website]. 2001-2007. Available at: http://www.icnfdr.org. Accessed October 7, 2007.
3. Saenz A., Mandal R., Kradin R., and Hedley-Whyte E.T. Nephrogenic fibrosing dermopathy with involvement of the dura mater. Virchows Archiv 449 (2006) 389-391
4. Quan T.E., Cowper S., Wu S.P., Bockenstedt L.K., and Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 36 (2004) 598-606
5. Swaminathan S., Ahmed I., McCarthy J.T., Albright R.C., Pittelkow M.R., Caplice N.M., et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 145 (2006) 234-235
6. Fazeli A., Lio P.A., and Liu V. Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link?. [letter]. Arch Dermatol 140 (2004) 1401
7. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 (2006) 1104-1108
8. Marckmann P., Skov L., Rossen K., Dupont A., Damholt M.B., Heaf J.G., et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 (2006) 2359-2362
9. U.S. Food and Drug Administration. Public health advisory: Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMark, Magnevist, ProHance, and MultiHance. June 8, 2006. Available at: http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htm. Accessed October 8, 2007.
10. High W.A., Ayers R.A., Chandler J., Zito G., and Cowper S.E. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56 (2007) 21-26
11. Boyd A.S., Zic J.A., and Abraham J.L. Gadolinum deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56 (2007) 27-30
12. Wiginton CD, Kelly B, Oto A, Jesse M, Aristimuno P, Ernst R, Chaljub G. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis and gadolinium detection in tissue. AJR 2008;190:1060-8.
13. Verrecchia F., and Mauviel A. Tranforming growth factor-β and fibrosis. World J Gastroenterol 13 (2007) 3056-3062
14. 1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 63 (2004) 423-432
15. Remuzzi G., Ruggenenti P., and Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 136 (2002) 604-615
16. Kawaguchi Y., Takagi K., Hara M., Fukasawa C., Sugiura T., Nishimagi E., et al. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II Type 1 receptors. Arthritis Rheum 50 (2004) 216-226
17. Morihara K., Takai S., Takenaka H., Sakaguchi M., Okamoto Y., Morihara T., et al. Cutaneous tissue angiotensin-converting enzyme may participate in pathologic scar formation in human skin. J Am Acad Dermatol 54 (2006) 251-257
18. Steckelings U.M., Wollschläger T., Peters J., Henz B.M., Hermes B., and Artuc M. Human skin: source of and target organ for angiotensin II. Exp Dermatol 13 (2004) 148-154
19. Jiménez S.A., Artlett C.M., Sandorfi N., Derk C., Latinis K., Sawaya H., et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor β1 expression in affected skin. Arthritis Rheum 50 (2004) 2660-2666
20. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown Jr. E.J., Cuddy T.E., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 (1992) 669-677
21. Pfeffer M.A., McMurray J.J.V., Velazquez E.J., Rouleau J.L., Køber L., Maggioni A.P., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
22. Schultz J.E.J., Witt S.A., Glascock B.J., Nieman M.L., Reiser P.J., Nix S.L., et al. TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 109 (2002) 787-796
23. Steen V.D., Costantino J.P., Shapiro A.P., and Medsger Jr. T.A. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113 (1990) 352-357
24. Pryor J.G., Poggioli G., Galaria N., Gust A., Robison J., Samie F., et al. Nephrogenic systemic fibrosis: a clinicopathologic study of six cases. J Am Acad Dermatol 57 (2007) 105-111
25. Tekeda H., Katagata Y., and Kondo S. Immunohistochemical study of angiotensin receptors in human anagen hair follicles and basal cell carcinoma. Br J Dermatol 147 (2002) 276-280
26. Leask A. Scar wars: is TGFβ the phantom menace in scleroderma?. Arthritis Res Ther 8 (2006) 213
27. Parsons A.C., Yosipovitch G., Sheehan D.J., Sangüeza O.P., Greenberg C.S., and Sane D.C. Transglutaminases: the missing link in nephrogenic systemic fibrosis. Am J Dermatopathol 29 (2007) 433-436
28. Denton C.P., Merkel P.A., Furst D.E., Khanna D., Emery P., Hsu V.M., et al. Recombinant human anti-transforming growth factor beta 1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 56 (2007) 323-333
29. Yang X., Letterio J.J., Lechleider R.J., Chen L., Hayman R., Gu H., et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 18 (1999) 1280-1291